Uncategorized
Early anti-VEGF switch yields improved response in cases of refractory DME
Patients with diabetic macular edema who were switched early to ranibizumab or aflibercept after not responding to bevacizumab experienced a statistically significant improvement in best corrected visual acuity. The retrospective study included 59 eyes of 45 patients, of which 17 eyes of 14 patients were switched to Eylea (aflibercept, Regeneron) and 42 eyes of 31 patients were switched to Lucentis (ranibizumab, Genentech) after not responding to treatment with Avastin (bevacizumab, Genentech) for DME. The aflibercept cohort previously had 5.76 injections compared with 4.1 injections in the ranibizumab cohort. Patients were (Read more...)